0JDK
:LSE

Add to watchlist
$23.81
Last updated:09/17/2021
0JDK: LSE
$23.81
Iovance Biotherapeutics Inc.

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product cand…

P/E ratio
-
vs. 0.00x forward
Stock volatility (Beta)
past 12 months
Become our supporter to unlock all data!
Company results
Qtr
Ann
Fundamentals
2017
2018
2019
2020
Net Income
Income minus expenses, depreciation, interest, taxes, and other expenses
Create free account to unlock
Cashflow
Sum up money going in and out company
Create free account to unlock
Total liabilities
All combined debts and obligations
Create free account to unlock
Company profile
CEO
Dr. Frederick G. Vogt Ph.D., Esq.
Market capitalization
Mid (2.19B)